Celon Pharma SA Cash Flow Conversion Efficiency

Latest as of March 2026: -0.009x

Celon Pharma SA cash flow conversion efficiency. Based on the latest financial reports, Celon Pharma SA (CLN) has a cash flow conversion efficiency ratio of -0.009x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-4.79 Million ≈ $-1.32 Million USD) by net assets (zł528.78 Million ≈ $145.53 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Celon Pharma SA worth for the company's overall valuation and market capitalisation.

Cash Flow Conversion Efficiency of Celon Pharma SA (2012–2025)

Cash flow conversion efficiency of Celon Pharma SA from 2012 to 2025. This chart illustrates how Celon Pharma SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CLN stock price and chart for real-time trading data and today's change.

Celon Pharma SA Cash Flow Conversion Ratio Explained

Celon Pharma SA cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Celon Pharma SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Celon Pharma SA ranked by their cash flow conversion efficiency. Review Celon Pharma SA (CLN) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.

Company	Cash Flow Conversion Efficiency
SEACOR Marine Holdings Inc NYSE:SMHI	-0.061x
Lemtech Holdings Co Ltd TW:4912	0.072x
Kross Ltd NSE:KROSS	0.010x
Dongkuk Steel Mill Co Ltd KO:001230	-0.018x
GRM Overseas Limited NSE:GRMOVER	0.004x
Gersan Elektrik Ticaret ve Sanayi AS IS:GEREL	-0.369x
Windlas Biotech Limited NSE:WINDLAS	0.013x
ARKO Petroleum Corp. NASDAQ:APC	0.040x

Annual Cash Flow Conversion Efficiency for Celon Pharma SA (2012–2025)

The table below shows the annual cash flow conversion efficiency of Celon Pharma SA from 2012 to 2025. Also see Celon Pharma SA asset portfolio for a full breakdown of the balance sheet.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	zł382.99 Million ≈ $105.40 Million	zł23.86 Million ≈ $6.57 Million	0.062x	+344.66%
2024-12-31	zł445.21 Million ≈ $122.53 Million	zł-11.34 Million ≈ $-3.12 Million	-0.025x	-36.49%
2023-12-31	zł445.56 Million ≈ $122.62 Million	zł-8.31 Million ≈ $-2.29 Million	-0.019x	-90.39%
2022-12-31	zł479.65 Million ≈ $132.01 Million	zł-4.70 Million ≈ $-1.29 Million	-0.010x	-112.35%
2021-12-31	zł554.00 Million ≈ $152.47 Million	zł43.95 Million ≈ $12.10 Million	0.079x	-51.36%
2020-12-31	zł434.67 Million ≈ $119.63 Million	zł70.90 Million ≈ $19.51 Million	0.163x	+1537.33%
2019-12-31	zł445.04 Million ≈ $122.48 Million	zł-5.05 Million ≈ $-1.39 Million	-0.011x	-118.03%
2018-12-31	zł448.73 Million ≈ $123.50 Million	zł28.24 Million ≈ $7.77 Million	0.063x	+9.40%
2017-12-31	zł439.85 Million ≈ $121.05 Million	zł25.30 Million ≈ $6.96 Million	0.058x	+12.15%
2016-12-31	zł402.50 Million ≈ $110.77 Million	zł20.65 Million ≈ $5.68 Million	0.051x	-90.13%
2015-12-31	zł100.82 Million ≈ $27.75 Million	zł52.37 Million ≈ $14.41 Million	0.519x	+48.46%
2014-12-31	zł69.62 Million ≈ $19.16 Million	zł24.36 Million ≈ $6.70 Million	0.350x	+116.14%
2013-12-31	zł52.20 Million ≈ $14.37 Million	zł8.45 Million ≈ $2.33 Million	0.162x	-30.09%
2012-12-31	zł55.57 Million ≈ $15.29 Million	zł12.87 Million ≈ $3.54 Million	0.232x	--

About Celon Pharma SA

WAR:CLN Poland Drug Manufacturers - Specialty & Generic

Market Cap

$201.33 Million

zł731.54 Million PLN

Market Cap Rank

#16377 Global

#107 in Poland

Share Price

zł18.80

Change (1 day)

-1.05%

52-Week Range

zł18.68 - zł23.50

All Time High

zł51.09